{"id":387408,"date":"2020-11-24T07:03:24","date_gmt":"2020-11-24T12:03:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387408"},"modified":"2020-11-24T07:03:24","modified_gmt":"2020-11-24T12:03:24","slug":"vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/","title":{"rendered":"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors<\/b><\/p>\n<p class=\"bwalignc\"><i>Mr. Ignelzi brings strong financial and operational expertise to the board and will serve as chairman of the Audit Committee<\/i><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vedantabio.com%2F&amp;esheet=52335588&amp;newsitemid=20201124005333&amp;lan=en-US&amp;anchor=Vedanta+Biosciences&amp;index=1&amp;md5=a6eadfb3ae1b5f579ca6f04a817dec0c\">Vedanta Biosciences<\/a>, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. Mr. Ignelzi has more than 25 years of experience supporting life science companies in finance, business development and operations, and has helped oversee their evolutions from privately held, clinical-stage companies to publicly traded biopharmaceutical companies preparing for commercial launches.\n<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20201124005333\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201124005333\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201124005333\/en\/841532\/4\/Ignelzi_Headshot.jpg\" alt=\"Vedanta Biosciences announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. Mr. Ignelzi has more than 25 years of experience supporting life science companies in finance, business development and operations, and has helped oversee their evolutions from privately held, clinical-stage companies to publicly traded biopharmaceutical companies preparing for commercial launches. (Photo: Business Wire)\" \/><\/p>\n<p style=\"font-size:85%\">Vedanta Biosciences announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. Mr. Ignelzi has more than 25 years of experience supporting life science companies in finance, business development and operations, and has helped oversee their evolutions from privately held, clinical-stage companies to publicly traded biopharmaceutical companies preparing for commercial launches. (Photo: Business Wire)<\/p>\n<\/div>\n<p>\n\u201cWe\u2019re excited to welcome Troy to the Vedanta board,\u201d said Bernat Olle, Ph.D., co-founder and chief executive officer of Vedanta Biosciences. \u201cTroy has a wealth of expertise in the biotech industry that can help guide our financial strategy as we move to our next phase of development.\u201d\n<\/p>\n<p>\nMr. Ignelzi has played a key role in seven IPOs, and currently serves as the chief financial officer of Karuna Therapeutics. He joined Karuna in March 2019, coming from scPharmaceuticals, where he was also in the role of chief financial officer, overseeing its transformation to a company preparing for commercial launch. Prior to scPharmaceuticals, Mr. Ignelzi was a senior executive at Juventas Therapeutics, Esperion Therapeutics and Insys Therapeutics, helping raise public and private capital, expand development pipelines through licensing and acquisition and advancing critical therapies, several of which are currently approved by the U.S. Food and Drug Administration. Mr. Ignelzi holds a B.A. in accounting from Ferris State University.\n<\/p>\n<p>\n\u201cThis is an exciting time for Vedanta and for the microbiome field,\u201d said Mr. Ignelzi. \u201cIn this position, I look forward to helping the Vedanta team advance defined bacterial consortia as a new drug modality.\u201d\n<\/p>\n<p><b>About Vedanta Biosciences<br \/>\n<br \/><\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vedantabio.com%2F&amp;esheet=52335588&amp;newsitemid=20201124005333&amp;lan=en-US&amp;anchor=Vedanta+Biosciences&amp;index=2&amp;md5=2b6bcbc42f4eee3ea8eb4bea8b8bd24c\">Vedanta Biosciences<\/a> is leading the development of a potential new category of oral therapies based on rationally defined consortia of bacteria derived from the human microbiome. The company\u2019s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk <i>C. difficile<\/i> infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy. These investigational therapies are grounded in pioneering research \u2013 published in leading journals including <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fscience.sciencemag.org%2Fcontent%2F331%2F6015%2F337&amp;esheet=52335588&amp;newsitemid=20201124005333&amp;lan=en-US&amp;anchor=Science&amp;index=3&amp;md5=f825a3fd1d409af77410818d2284efb9\"><i>Science<\/i><\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnature12331&amp;esheet=52335588&amp;newsitemid=20201124005333&amp;lan=en-US&amp;anchor=Nature&amp;index=4&amp;md5=de66c3441aa3e045ed06f01769dda34e\"><i>Nature<\/i><\/a>, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F26411289&amp;esheet=52335588&amp;newsitemid=20201124005333&amp;lan=en-US&amp;anchor=Cell&amp;index=5&amp;md5=471401a8a248efc350a9f5c9393791f9\"><i>Cell<\/i><\/a><i \/>\u2013 to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens and induce a range of potent immune responses. Vedanta Biosciences controls a foundational portfolio of more than 40 patents and has built what is believed to be the world\u2019s biggest library of bacteria derived from the human microbiome. Proprietary capabilities include deep expertise in consortium design, vast datasets from human interventional studies and cGMP-compliant manufacturing of oral live biotherapeutics containing pure, clonally derived bacterial consortia in powdered form. Vedanta Biosciences was founded by <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=52335588&amp;newsitemid=20201124005333&amp;lan=en-US&amp;anchor=PureTech+Health&amp;index=6&amp;md5=c1d0711a67bfc8e7ee711b26d7637ede\">PureTech Health<\/a> (LSE:PRTC, Nasdaq:PRTC) and a global team of scientific co-founders who pioneered Vedanta\u2019s modern understanding of the cross-talk between the microbiome and the immune system.\u00a0\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201124005333r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201124005333\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201124005333\/en\/<\/a><\/span><\/p>\n<p><b>Investors and Media<br \/>\n<\/b><br \/>Allison Mead Talbot<br \/>\n<br \/>+1 617 651 3156<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:amt@puretechhealth.com\">amt@puretechhealth.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Managed Care Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201124005333\/en\/528400\/3\/Vedanta_Biosciences.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201124005333\/en\/841532\/3\/Ignelzi_Headshot.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">Vedanta Biosciences announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. Mr. Ignelzi has more than 25 years of experience supporting life science companies in finance, business development and operations, and has helped oversee their evolutions from privately held, clinical-stage companies to publicly traded biopharmaceutical companies preparing for commercial launches. (Photo: Business Wire)<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors Mr. Ignelzi brings strong financial and operational expertise to the board and will serve as chairman of the Audit Committee CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. Mr. Ignelzi has more than 25 years of experience supporting life science companies in finance, business development and operations, and has helped oversee their evolutions from privately held, clinical-stage companies to publicly traded biopharmaceutical companies preparing for commercial launches. This press release features &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-387408","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors Mr. Ignelzi brings strong financial and operational expertise to the board and will serve as chairman of the Audit Committee CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. Mr. Ignelzi has more than 25 years of experience supporting life science companies in finance, business development and operations, and has helped oversee their evolutions from privately held, clinical-stage companies to publicly traded biopharmaceutical companies preparing for commercial launches. This press release features &hellip; Continue reading &quot;Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T12:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20201124005333\/en\/841532\/4\/Ignelzi_Headshot.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors\",\"datePublished\":\"2020-11-24T12:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\\\/\"},\"wordCount\":690,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20201124005333\\\/en\\\/841532\\\/4\\\/Ignelzi_Headshot.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\\\/\",\"name\":\"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20201124005333\\\/en\\\/841532\\\/4\\\/Ignelzi_Headshot.jpg\",\"datePublished\":\"2020-11-24T12:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20201124005333\\\/en\\\/841532\\\/4\\\/Ignelzi_Headshot.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20201124005333\\\/en\\\/841532\\\/4\\\/Ignelzi_Headshot.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors - Market Newsdesk","og_description":"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors Mr. Ignelzi brings strong financial and operational expertise to the board and will serve as chairman of the Audit Committee CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the appointment of Troy Ignelzi as an independent member of its Board of Directors. Mr. Ignelzi has more than 25 years of experience supporting life science companies in finance, business development and operations, and has helped oversee their evolutions from privately held, clinical-stage companies to publicly traded biopharmaceutical companies preparing for commercial launches. This press release features &hellip; Continue reading \"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T12:03:24+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20201124005333\/en\/841532\/4\/Ignelzi_Headshot.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors","datePublished":"2020-11-24T12:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/"},"wordCount":690,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20201124005333\/en\/841532\/4\/Ignelzi_Headshot.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/","name":"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20201124005333\/en\/841532\/4\/Ignelzi_Headshot.jpg","datePublished":"2020-11-24T12:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20201124005333\/en\/841532\/4\/Ignelzi_Headshot.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20201124005333\/en\/841532\/4\/Ignelzi_Headshot.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vedanta-biosciences-appoints-troy-ignelzi-chief-financial-officer-at-karuna-therapeutics-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=387408"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387408\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=387408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=387408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=387408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}